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Abstract 
Purpose: To determine frequency of routine radiological staging of breast cancer patients diagnosed in a German 
Breast Cancer Screening Center from 2007 to 2014, the incidence and consequences of distant metastases detected 
and the resulting implications for clinical routine.
Methods: Records of 896 patients with primary breast cancer diagnosed in the Screening Centre and treated in five 
participating hospitals were analyzed retrospectively. Evaluation included frequency and type of staging procedures 
and results with respect to distant metastasis and their consequences on clinical management.
Results: 894/896 Patients (99.8 %) received staging for distant metastases by bone scintigraphy, chest X‑ray and liver 
sonography and/or CT/MRT diagnostics. Distant metastasis was suggested In 6/894 patients but excluded in 3 by 
further diagnostics or clinical course. Thus, 3 (0.3 %) were clinically verified to have metastatic disease in bone (n = 2; 
both pT2) or in bone and lung (n = 1; cT4, cN3).
Conclusion: Due to the low incidence of verified metastatic disease, the high false positive rate of staging proce‑
dures and the unfavorable cost/benefit ratio routine radiological staging should be completely omitted in asympto‑
matic breast cancer patients diagnosed in a breast cancer screening programme.
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Background
Breast cancer is the most frequent malignant disease in 
women in Europe; in Germany the incidence is 70,000 
new breast cancer diagnoses annually (Kaatsch et  al. 
2014). Aiming at an improved breast-cancer-therapy sev-
eral countries introduced screening-programs for early 
breast cancer detection by mammography (Giordano 
et  al. 2012; Shapiro et  al. 1998). In Germany a suchlike 
program started in accordance with European guide-
lines in 2004, since 2009 a region wide maintenance 
exists in all 16 states, organized in more than 94 so-called 
Breast-Cancer-Screening-Units. The German Breast-
Cancer-Screening-Programme invites breast-healthy 
women of 50–69 years of age in a 2-year-interval by the 
local residents` registration offices. After diagnosis of 
breast cancer via Screening-Programme further onco-
logical treatment follows national and international 
guidelines. Although a routine radiological staging for 
exclusion of distant metastasis in early breast cancer is 
not recommended by current guidelines (Kreienberg 
et al. 2013; Gradishar et al. 2016), it seems still to be per-
formed in the majority of patients (Chand et  al. 2013; 
Simos et  al. 2015). Modalities focus on organs which 
would be primarily involved: the skeletal system via 
whole-body-scintigraphy, the lung via chest-X-ray and 
the liver via ultrasound and/or CT- or MRI-scan in some 
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cases. Thus, in this study we analyzed the frequency of 
radiological routine staging in breast cancer patients 
diagnosed in a German Breast-Cancer-Screening-Center 
from 2007 to 2014, the findings and their consequences 
on further treatment. The results should give insight into 
the clinical routine management in the region investi-
gated and will be discussed with respect to side effects, 
e.g. cost/benefit-ratio.
Methods
896 Patients who were diagnosed with primary breast 
cancer in the German Breast Cancer Screening Center 
Diavero®/Essen between 2007 and 2014 via the German 
Mammography-Screening-Programme were included 
in the study. For these patients the records of Diavero® 
and the five in the study participating hospitals have 
been analyzed with respect to type and results of staging 
procedures to preclude distant metastasis and whether 
these results changed the oncological treatment plan. 
All research presented in this paper was conducted in 
accordance with the ethical research standards of the 
local ethics committee.
The characteristics of the patients and the initial 
tumor stages are summarized in Fig. 1 and Tables 1 and 
2 (T =  tumor size; N =  nodal involvement; n.k. =  not 
known).  
Patients with detected early breast cancer in the 
National Screening Programme at Diavero® were sent to 
treating hospitals of their choice afterwards. This work 
evaluates all patients referred to one of the five hospitals 
participating in this study. Staging procedures for detec-
tion of metastases were conducted after hospitals own 
standards. Decision on oncological treatment was made 
in local interdisciplinary tumor board and submitted as 
proposal to the patient.
Results
Incidence, modality and timing of staging
894/896 (99.8 %) of the patients received a routine stag-
ing for distant metastasis. In 618 (69  %) detailed infor-
mation about the modality of staging was known: 340 
Patients had the “classical approach” of a whole-body-
scintigraphy, a chest-X-ray and a liver-ultrasound, but in 
33 cases use of an additional modality like CT, PET-CT 
or MRI to exclude metastases was documented. On the 
other hand 278 cases got a non-conventional staging by 
CT scan as a substitute for X-ray or ultrasound, but still 
in 3 cases an additional CT, PET-CT or MRI was neces-
sary to exclude metastases.
In 276 cases the staging result of bone, lung and liver is 
known—but no report was available to verify the staging 
modality used. In 2 patients only a staging was omitted, 
so they were assigned to MX-Status.
In 236 cases timing of staging with respect to the start 
of oncological treatment could be evaluated: 198 patients 
(84  %) had a complete staging preoperatively, n  =  38 
postoperatively (16 %).
Results of staging (M0, M1, MX)
In 6 of 894 patients with radiological staging metastatic 
spread to the skeletal system (and lung in one case) at 
point of primary breast cancer diagnosis has been sug-
gested. In three of these evidence for metastasis in imag-
ing was highly conclusive, so these patients were assigned 
to palliative treatment without histological confirmation. 
One of them, however, was diagnosed with a stage cT4-
tumor, thus in fact she did not fulfill criteria for participa-
tion in German Mammography Screening, which aims at 
woman without clinical signs of breast cancer.
In a 4th case the patient reported a traumatic event in 
medical history as a differential diagnosis for bone metas-




































Fig. 1 a Age‑distribution. b Histological type
Table 1 Prior mammography in medical history








n 249 210 26 274 137
% 28.1 23.1 3.1 30.6 15.1
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Follow-ups did not confirm distant metastasis and this 
patient remained in adjuvant treatment concept.
A 5th patient had the initial staging suspicion of bone-
metastasis but treatment choice remained adjuvant. Fol-
low-ups by whole-body-scintigraphy and MR-scan finally 
excluded bone metastases.
In a 6th patient the suspicion of distant bone metasta-
sis was excluded via biopsy. The histological result con-
firmed the patients hyperparathyreoidism as the cause 
for multiple osteolytic lesions in imaging. The patient was 
finally staged M0, treatment followed adjuvant criteria.
Implications for oncological treatment
The oncological concept has been modified in 3/894 
patients due to the findings in staging for distant disease. 
Characteristics of the patients and treatment chosen are 
reported.
Patient 1
The 68 year old patient had bowel-cancer in medical his-
tory 30 years ago. She was first time participating in Ger-
man Breast Cancer Screening Programme. She presented 
with a screening-detected hormone-receptor-positive 
ductal invasive breast cancer, G2, Ki67 = 20 %. Mastec-
tomy was done at the patients request with sentinel-node 
axillary staging. The histological result was pT2 pN0 
(sn-) L0 R0. The postoperative staging by whole-body-
scintigraphy showed suspicion of bone metastasis, which 
was confirmed by MR- and CT-scan. Due to imaging—
but without histological confirmation—the patient was 
assigned to palliative endocrine therapy and bone-mod-
ifying RANKL-antibody (Denosumab) and additional 
radiotherapy of pelvic bone metastasis.
Patient 2
In the 59  year old patient a hormone-receptor-positive 
ductal invasive breast cancer was diagnosed. Breast 
conserving therapy and axillary staging resulted in pT2 
pN1a G3 ER90  % PR90  % Her2neg breast cancer. Tim-
ing of staging was not known but resulted in suspicion of 
bone metastasis to the lumbar spine and was confirmed 
by MR-scan. The patient has been treated deviating from 
guidelines by 4 cycles of epirubicin/cyclophosphamide 
chemotherapy followed by aromatase inhibitors. Bispho-
sphonates and local radiotherapy of the lumbar spine 
were added.
Patient 3
The 58  year old patient was first time participating in 
Screening, but presented with an inflammatory cT4 
breast cancer and clinical signs of axillary lymph node 
metastasis. Histology confirmed a ductal invasive type 
of breast cancer, hormone-receptor-positive, Her2-nega-
tive, no Ki67-value was documented. Staging showed dis-
tant metastasis in bone and lung which lead to palliative 
chemotherapy with Paclitaxel and anti-VEGF-antibody 
Bevacizumab.
Patients 4–6, whose metastasis were not confirmed, 
were between 60 and 65  years old. All of them showed 
invasive ductal breast cancer, pT1c, pN0 (sn-), G2, R0. 
Metastasis could be precluded by follow up control in 
2 patients, and by biopsy in 1 patient, which revealed a 
hyperparathyroidism. All were treated in the adjuvant 
protocol according to the current guidelines.
Discussion
International and also the German Breast Cancer-Screen-
ing-Programme by mammography aim at improving cure 
for breast-cancer with respect to breast cancer specific 
mortality and overall survival concomitantly reducing 
patients burden by unnecessary diagnostics or treatment 
due to early diagnosis (Waters and Porter 2014; Austral-
ian Institute of Health and Welfare 2016).
However, with respect to different treatment proto-
cols in the adjuvant and palliative setting it is important 
to preclude metastatic disease in patients diagnosed 
with breast cancer. This leads to routine clinical diag-
nostics in all breast cancer patients for the detection of 
lung, liver and bone metastases (Chand et al. 2013; Simos 
et  al. 2015; Puglisi et  al. 2005; Rayson and Porter 2015; 
Myers et al. 2001). On the other hand, incidence of dis-
tant metastasis in early breast cancer is low (Puglisi et al. 
2005; Barrett et  al. 2009; Norum and Andreassen 2000) 
and staging is accompanied by a high percentage of 
Table 2 T-, N-Status, Grading
T-Status n % N-status n % Grading n %
1 689 76.9 N 0 696 77.7 1 213 23.8
2 180 20.1 N 1 142 15.8 2 485 54.1
3 16 1.8 N 2 35 3.9 3 154 17.2
4 5 0.5 N 3 14 1.6 n.k. 44 4.9
n.k. 6 0.7 n.k. 9 1.0
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false positives (Myers et  al. 2001; Norum and Andreas-
sen 2000; Nomura et al. 1978), therefore, routine staging 
for metastasis in asymptomatic early breast cancer is no 
longer recommended in a variety of national and interna-
tional guidelines (Kreienberg et al. 2013; Gradishar et al. 
2016; Brennan and Houssami 2012; Ravaioli et al. 2002).
Although, the first recommendations not to stage 
asymptomatic patients with early breast cancer have 
been published almost 40 years ago (Nomura et al. 1978; 
Butzelaar et  al. 1977), this seems not to be generally 
implemented in clinical routine up to now (Simos et  al. 
2015; Waters and Porter 2014; Simos and Clemons 2014). 
Chand et  al. (Chand et  al. 2013) could show that in the 
UK neither the indication nor the staging modality has 
been uniformly agreed upon by the UK Breast Surgeons. 
Same has been reported for Canada (Simos and Clemons 
2014). In Germany, staging for distant metastases in early 
breast cancer also still seems to be widely spread at pre-
sent in spite of the low detection rate (Debald et al. 2014).
Since breast cancer patients diagnosed in a national 
screening programme usually suffer from early asympto-
matic disease, analysis of frequency of radiological stag-
ing, incidence and consequences of distant metastases 
may give randomly insight in current clinical routine. The 
result of 99.8 % patients staged for distant metastases in 
our region impressively confirmed the nonconformity of 
current clinical practice to scientific findings and result-
ing clinical guidelines. Even after the publication of the 
“Top Five List for Oncology” of ASCO in 2012 (Schnip-
per et al. 2012) no change was observed.
The diagnosis of distant metastases (bone) has been 
made in 2/896 (0.2 %) asymptomatic patients and no liver 
or lung metastases were observed (the patient with cT4 
tumour had been excluded due to symptomatic disease). 
This extremely low rate of metastases corresponds well to 
that reported for stage I and II breast cancer in the UK 
(Barrett et al. 2009). The diagnosis of bone metastases in 
the two patients lead to changes in treatment protocol. 
However, there is no evidence that this change has any 
impact on survival; on the other hand toxicity of systemic 
treatment has been reduced at least in one patient. This, 
however, has to be balanced against the strain of three 
patients with false positive findings, who might have suf-
fered from additional diagnostics and the psychological 
burden of diagnosis of incurable disease and its sequelae.
Apparently, approximately 3000 diagnostic staging pro-
cedures were performed unnecessarily. 894/896 patients 
of this cohort had to tolerate diagnostic procedures with-
out any benefit. In principal, each exposure with ioniz-
ing radiation increases the risk of mutation and insofar 
incidence of cancer (Berrington de González and Darby 
2004); a conventional staging with bone scintigraphy and 
chest X-ray causes 1.5 times more radiation load than 
natural exposure (2.1  mSv) throughout the year (Fed-
eral Office for Radiation Protection 2015). While basic 
radiological diagnostics will at least contribute to accu-
mulation of ionizing exposure during lifetime additional 
diagnostic procedures will even increase the risk (Ber-
rington de González and Darby 2004; Huang et al. 2009): 
in our collective more than one third (34 %) of examina-
tions was associated with an extra radiation burden by 
use of CT or PET-CT for initial or extended staging in 
unclear cases. So direct burden will not only result from 
ionizing exposure but also from the risk of false posi-
tive results (Myers et al. 2001; Barrett et al. 2009) imply-
ing incurable disease. Besides that patients are exposed 
to unnecessary fear and distress waiting for their final 
results (Flory and Lang 2011; Baqutayan and Mohamed 
2012)—especially if the suspicion of metastasis remains 
unsolved.
Economically, cost for staging procedures vary between 
countries; Morris et  al. calculated cost of € 50,850/per 
case diagnosed with bone metastases in a center in Ire-
land (Morris et al. 2009). In Germany—depending on the 
medical fee schedule—cost for bone scintigraphy, chest 
X-ray and liver sonography range between 100 and 170€ 
per case without any additional diagnostics. Additional 
CT or even PET-scan leads to costs more than twice as 
much (Kassenärztliche Bundesvereinigung 2016; 2008). 
With respect to the annually new breast cancer diagnoses 
of stage I and II in Germany (Eisemann et al. 2013) this 
alone would generate between 5 Mio € and 20 Mio €/year 
for unnecessary staging.
In conclusion, the chance to be free of detectable dis-
tant metastases in our cohort of patients diagnosed 
within the national breast cancer screening programme 
has been > 99.5 % (Brennan and Houssami 2012; Debald 
et  al. 2014)and this correlates well with the results of 
other studies with respect to asymptomatic breast cancer 
stage I and II. These findings contrast to the observation 
that 99.8  % in fact received radiological routine staging 
for distant metastases. As outlined it is obvious that rou-
tine clinical staging for distant metastases under these 
conditions will only harm the patients and not benefit at 
all. Even for clinical studies it should be evaluated strictly 
whether staging for distant metastases in early breast 
cancer is justified with respect to the extremely low prev-
alence and to the potential damage in the individual set-
ting. Independently of medical aspects, the money spent 
for unnecessary staging procedures will lack for other 
services of the health care systems.
Thus, there is no argument any longer justifying radio-
logical staging in asymptomatic breast cancer patients 
stage I and II or diagnosed in a screening program, 
neither with respect to safety, nor to forensic or eco-
nomic reasons. Staging under these conditions has to 
Page 5 of 5Rusch et al. SpringerPlus  (2016) 5:1010 
be omitted completely not only in guidelines but also in 
clinical practice.
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